CRISPR Gene Drives and the Future of Evolution
By Hannah Thomasy,
The Scientist
| 03. 15. 2024
Today, Massachusetts Institute of Technology biologist Kevin Esvelt is well known for his work on guided evolution technologies—creating systems for evolving biomolecules in the lab and developing techniques to shape the evolutionary trajectories of species in the wild—as well as forging new pathways to safeguard these technologies from misuse.1,2
Esvelt’s entanglement with evolution began early. As a child, he visited the Galápagos, and was captivated by the islands’ stunning array of unique wildlife. “That sparked an interest in the evolution of creatures in the natural world,” said Esvelt. “It got me reading Darwin. And I started wondering—could we make things of comparable magnificence?”
So, when he joined David Liu’s research group at Harvard University for his graduate studies in 2004, he jumped into exploring how to put evolutionary processes to work in the lab. “I love solving problems that I am not actually smart enough to solve. And to do that, you need access to something that is effectively smarter than you, or at least can execute search strategies that you can’t,” said Esvelt. “One of the...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...